Header: Concert Joins Lyric; by Chat GPT
Concert Joins Lyric—Finding a Much Larger Stage for Precision-Health Intelligence
Big news arrived from Nashville on July 15: Concert, known for most of its history as Concert Genetics, has been acquired by Lyric, the large healthcare payment-accuracy and “decision intelligence” company. For those who have followed Concert and its outstanding executive team over the years, the transaction looks less like an abrupt change of direction than the logical culmination of a long effort to make the extraordinarily complex world of genetic and laboratory testing understandable—and computable.
Concert was founded in 2010 as NextGxDx, initially creating tools that helped clinicians find, compare, and order genetic tests. It became Concert Genetics in 2017 and, since 2024, has generally used the shorter name Concert. Over time, the company expanded well beyond a test directory. Its infrastructure now includes proprietary laboratory-market data, clinical and coding expertise, the Concert GTU test-identification system, and patented technology for converting medical policies into machine-readable rules that can be used in ordering, coverage, coding, claims editing, and payment. Concert reports that its registry has grown to more than 175,000 laboratory-testing products and that, by 2023, its health-plan customers represented about 30 million members. (Concert)
The acquisition brings those capabilities into a much larger operating environment. Lyric grew out of the ClaimsXten payment-accuracy business and says its technology is used by nine of the ten largest U.S. health plans, supporting approximately 200 million covered lives. Its Lyric42 platform applies policy, coding, clinical information, and artificial intelligence to claims workflows, with an emphasis on decisions that are fast, auditable, and explainable. (Business Wire)
This is not a first date. Concert and Lyric began working together in 2023, initially integrating Concert’s genetic-testing capabilities with Lyric’s claims-editing platform. In 2024, they expanded the relationship into a broader Diagnostics Module covering both advanced and routine outpatient laboratory services. According to the acquisition announcement, the scope and impact of their joint solution have grown nearly tenfold since the partnership began. (Business Wire)
Concert Chief Science Officer Gillian Hooker described the company’s journey as one of scale: “taking what is possible scientifically and making it possible for more people, clearly and transparently.” She added that this next step is also about scale. That seems exactly right. Concert has spent more than a decade addressing the difficult intellectual work: identifying tests, organizing evidence, translating clinical policy into structured logic, and connecting that logic to coding and payment. Lyric supplies the industrial-scale distribution system through which those capabilities can reach a far larger share of the health-insurance market.
The strategic importance extends beyond genetics. Health plans must now manage a rapidly changing mixture of molecular diagnostics, large sequencing panels, infectious-disease testing, companion diagnostics, specialty drugs, personalized therapies, and other services for which the clinical evidence and coding rules may change faster than conventional payer systems can be updated. A policy written as a PDF and interpreted manually at disconnected points in the claims process is increasingly inadequate. Concert’s approach is to make the policy simultaneously readable by humans and executable by machines—and to place it inside the systems where ordering and payment decisions actually occur.
Concert CEO Rob Metcalf has emphasized that clinical and administrative policies should be transparent, evidence-based, and computable. Joining Lyric provides a route for putting that philosophy into real-time payer workflows on a national scale. In that sense, this is not simply the acquisition of a respected Nashville consultancy and technology company. It is another sign that precision-medicine management is moving from a specialized corner of laboratory benefits into the mainstream infrastructure of health-plan claims and payment operations.
Congratulations are due to Rob Metcalf, Gillian Hooker, and the entire Concert team. Concert’s executives have been thoughtful, visible, and constructive participants in the laboratory and genomics community for many years. Their work helped bring order to a field in which scientific innovation has often moved much faster than coverage, coding, and payment systems. Under Lyric, they will have a substantially larger platform—and a great deal more scale—on which to continue that work.
